BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hou YC, Zheng CM, Yen TH, Lu KC. Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection. Int J Mol Sci 2020;21:E7833. [PMID: 33105763 DOI: 10.3390/ijms21217833] [Cited by in Crossref: 5] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Kolkhof P, Lawatscheck R, Filippatos G, Bakris GL. Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone—Translational Aspects and Clinical Perspectives across Multiple Organ Systems. IJMS 2022;23:9243. [DOI: 10.3390/ijms23169243] [Reference Citation Analysis]
2 Charaya K, Shchekochikhin D, Andreev D, Dyachuk I, Tarasenko S, Poltavskaya M, Mesitskaya D, Bogdanova A, Ananicheva N, Kuzub A. Impact of dapagliflozin treatment on renal function and diuretics use in acute heart failure: a pilot study. Open Heart 2022;9:e001936. [PMID: 35609943 DOI: 10.1136/openhrt-2021-001936] [Reference Citation Analysis]
3 Cheang I, Liao S, Zhu Q, Ni G, Wei C, Jia Z, Wu Y, Li X. Integrating Evidence of the Traditional Chinese Medicine Collateral Disease Theory in Prevention and Treatment of Cardiovascular Continuum. Front Pharmacol 2022;13:867521. [PMID: 35370696 DOI: 10.3389/fphar.2022.867521] [Reference Citation Analysis]
4 Keller DM, Ahmed N, Tariq H, Walgamage M, Walgamage T, Mohammed A, Chou JT, Kałużna-Oleksy M, Lesiak M, Straburzyńska-Migaj E. SGLT2 Inhibitors in Type 2 Diabetes Mellitus and Heart Failure-A Concise Review. J Clin Med 2022;11:1470. [PMID: 35329796 DOI: 10.3390/jcm11061470] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Schlögl H, Stumvoll M. The Brains Behind SGLT2 Inhibition. Diabetes Care 2022;45:273-5. [PMID: 35050363 DOI: 10.2337/dci21-0050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Rizzo MR, Di Meo I, Polito R, Auriemma MC, Gambardella A, di Mauro G, Capuano A, Paolisso G. Cognitive impairment and type 2 diabetes mellitus: Focus of SGLT2 inhibitors treatment. Pharmacol Res 2022;176:106062. [PMID: 35017046 DOI: 10.1016/j.phrs.2022.106062] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Hazem RM, Ibrahim AZ, Ali DA, Moustafa YM. Dapagliflozin improves steatohepatitis in diabetic rats via inhibition of oxidative stress and inflammation. Int Immunopharmacol 2022;104:108503. [PMID: 34998036 DOI: 10.1016/j.intimp.2021.108503] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
8 Zhang F, Wang W, Hou X. Effectiveness and safety of ertugliflozin for type 2 diabetes: A meta-analysis of data from randomized controlled trials. J Diabetes Investig 2021. [PMID: 34610204 DOI: 10.1111/jdi.13688] [Reference Citation Analysis]
9 Gupta M, Rao S, Manek G, Fonarow GC, Ghosh RK. The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence. Ther Clin Risk Manag 2021;17:823-30. [PMID: 34408424 DOI: 10.2147/TCRM.S275076] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
10 Duan S, Lu F, Song D, Zhang C, Zhang B, Xing C, Yuan Y. Current Challenges and Future Perspectives of Renal Tubular Dysfunction in Diabetic Kidney Disease. Front Endocrinol (Lausanne) 2021;12:661185. [PMID: 34177803 DOI: 10.3389/fendo.2021.661185] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
11 Leoncini G, Russo E, Bussalino E, Barnini C, Viazzi F, Pontremoli R. SGLT2is and Renal Protection: From Biological Mechanisms to Real-World Clinical Benefits. Int J Mol Sci 2021;22:4441. [PMID: 33922865 DOI: 10.3390/ijms22094441] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
12 Winiarska A, Filipska I, Knysak M, Stompór T. Dietary Phosphorus as a Marker of Mineral Metabolism and Progression of Diabetic Kidney Disease. Nutrients 2021;13:789. [PMID: 33673618 DOI: 10.3390/nu13030789] [Reference Citation Analysis]
13 Elkazzaz SK, Khodeer DM, El Fayoumi HM, Moustafa YM. Role of sodium glucose cotransporter type 2 inhibitors dapagliflozin on diabetic nephropathy in rats; Inflammation, angiogenesis and apoptosis. Life Sci 2021;280:119018. [PMID: 33549594 DOI: 10.1016/j.lfs.2021.119018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]